Antimicrobial Copper changing the course of Medicine History on the 21st century.
|
|
- Joy McCormick
- 5 years ago
- Views:
Transcription
1 Antimicrobial Copper changing the course of Medicine History on the 21st century. Panos A. Efstathiou M.D., D.Sc. Orthopedic Surgeon Secretary General of Hellenic College of Orthopedic Surgeon On the 19th century Louis Pasteur has developed the germ theory of disease and its affect on the human body. On the 20th century Alexander Fleming 1 discovered an infection-fighting agent, widely known as penicillin. They were both major discoveries that would change the course of Medicine History. On the 21st century Antimicrobial Copper Alloys has proved to be the most sufficient, accurate and low cost antibacterial agents, reducing significantly the microbial flora on touch surfaces. Copper use from different civilizations in the course of time Copper and its beneficial actions in humans are already known since the early years. The name origins from the Latin name curpus indicating the name of the island of Cyprus which was the main source of mineral cooper in antiquity 2. The use of containers of drinking water from copper and the installation of metal shaving in the wounds for disinfection is reported in Egypt 3. The Aztecs used cooper to treat various skin diseases 2. Hippocrates, the father of Medicine ( B.C.E) recommended the use of copper for leg ulcers related to varicose veins 2. In France during the cholera epidemic of 1850 A.C.E, it was observed that workers in copper mines were not affected by the disease 3. In 1970, antimicrobial copper activity has been observed by the American College of Chest Physicians, and compiled the first publication on Antibacterial Action of Copper in Respiratory Therapy Apparatus. The oligodynamic effects of introducing copper into large reservoir nebulizers used in respiratory therapy has resulted in the nebulizer contents remaining in a sterile state 4. In 1983, a hospital study showing cooper s effectiveness in lowering the E.Coli count on doorknobs was published in the United States of America 5. During the next decades the major concern within the medical community is Health Care Associated Infections (HCAI), or nosocomial infections. These infections affect patients in a hospital or other health care facility, and are not present or incubating at the time of admission. They also include infections acquired by patients in the hospital or facility but appearing after discharge, and occupational infections among staff 6. According to fact sheet of WHO (2011) most countries lack surveillance systems for health care-associated infections 7. Those that do have systems often struggle with the complexity and lack of standardized criteria for diagnosing the infections. 1
2 While this makes it difficult to gather reliable global information on health care associated infections, results from studies clearly indicate that each year, hundreds of millions of patients are affected by them around the world 7. Health care-associated infections usually only receive public attention when there are epidemics. Although often hidden from public attention, the very real endemic, on-going problem is one that no institution or country can claim to have solved, despite many efforts. Recently the E. Coli-0104:H4 outbreak in Germany, which is known (never before seen) as a country with strong and well organised health system, points out the difficulty of discovering the source of epidemic 8. Prevalence of health care-associated infection in high income countries, (WHO Report on the Burden of Endemic Health Care-Associated Infection World wide2011 The European Centre for Disease Prevention and Control reports an average prevalence of HCAI is 7.1% in European Countries. The Centre estimates that patients are affected by approximately episodes of health careassociated infection every year in Europe 9. The estimated incidence rate in the United States of America (USA) was 4.5% in 2002, corresponding to 9.3 infections per patient-days and 1.7 million affected patients 10. According to a recent European multicenter study, the proportion of infected patients in intensive care units can be as high as 51%; most of these are health care-associated 11. Approximately 30% of patients in ICUs are affected by at least one episode of health care associated infection. The longer patients stay in an ICU, the more at risk they become of acquiring an infection. On average, the cumulative incidence of infection in adult-high risk patients is 17.0 episodes per 1000 patient-days 11. 2
3 The measures taken for eliminating-reducing microbes transportation through frequently touch surfaces started the last decade with the Clean Care is Safer Care campaign (WHO) 12. In many healthcare systems, specific guideline was given to healthcare professionals, in order to activate their awareness and eliminate nosocomial infections. In 2001 in the UK, the epic Project: Developing National Evidence-based Guidelines for Preventing Healthcare associated Infections among the other good practices, points out touch surfaces as one of the major components of microbes concentration and transfer 13. Laboratory studies In 1995 first laboratory researches from the University of Southampton showed that the copper cast alloys was able to control E.-Coli 0157 in cross contamination food procedures 14. The results of the above research showed that although stainless steel surfaces may appear to be clean, bacteria can survive on these surfaces for considerable periods of time. In comparison, survival on many copper alloys is limited to just a few hours or even minutes. Due to the intrinsic characteristics of copper alloys, i.e. homogenous and solid, superior lifetime antimicrobial efficacy, wear resistance, and durability, they could be utilized in facilities where bacterial contamination cannot be tolerated 14. On the following years in many laboratory researches, germicide activity of copper alloys has been identified 15, 16and 17. Clinical Trials First clinical trial results in Kitasato University Hospital in Japan, Selly Oak Hospital in the UK and Calama Hospital in Chile, showed that surface contamination was greatest on surfaces near the patient. The second results showed 90% reductions in contamination on copper surfaces compared to controls. Neither MRSA nor VRE were found on any copper 18, 19, and 20 surface sampled In an outpatient study, not only was the reduction in Microbial Burden confirmed but a halo effect was observed-reduced contamination in the vicinity of the copper surfaces. The copper surfaces were also shown to reduce the risk of exposure to environmental microbes by 17% 7. Other clinical trials come to confirm the significant reduction in contamination on the copper compared to the control components. (Asklepios Hospital, Hamburg, Germany) 21 In addition first results show higher levels of contamination on the non-copper items and presence of faecal and urinary bacteria (Staphylococcus aureus, E.Coli and Candida albicans) only on stainless steel, plastic and chromium components. On copper and copper alloy surfaces, only Gram positive bacilli and cocci and normal environmental and skin flora were found. (Helsinki University: Department of Public Health, Finland.) 22 3
4 Antimicrobial Copper Alloys Registration During the 2008, in the US, laboratory results were independently verified by the Environmental Protection Agency (EPA), leading to EPA having the only public health registration for a touch surface material. The innovation was that for the first time a solid material has been registered and approved for its germicide efficacy, suitable for public health usage. Researches took place in 3 US hospitals, Memorial Sloan-Kettering Cancer Center, NY, Ralph H. Johnson Veterans Administration Medical Center, NY and Medical University of South Carolina, Charleston, SC. 23 The trials are being executed in three stages. The first stage established the baseline microbial burden on frequently-touched objects in ICU rooms. The second stage, which has just been completed, compared the microbial burden on Antimicrobial Copper surfaces with the microbes found on non copper equivalent surfaces. The third stage will assess the incidence of hospital-acquired infections in ICU rooms with and without Antimicrobial Copper Objects. 23 The connection between contamination on frequently-touched surfaces and patient acquisition of infections evaluated in order to determine, that Antimicrobial Copper has a clinical benefit to patients. Findings from the first stage of the program show that the most heavily contaminated objects are those in closest proximity to the patients: bed rails, call buttons and chairs were found to the highest levels of Staphylococcus aureus, methicillinresistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). These pathogens can survive for extended periods of time on such objects, which may act as reservoirs for the bacteria. The average microbial burden on objects was nearly 17,000 Colony forming Units per 100 square centimetres. 23 Similar researches from the WHO 7 and the Medical University of South Carolina show that objects located close to the patient are most heavily contaminated. These objects are mainly bed rails and call buttons 24. In general Antimicrobial Copper Alloys are effective against bacteria viruses, fungi and moulds, including Staphylococcus aureus (MRSA), Influenza A (H1N1), Enterobacter aerogenes, Pseudomonas aeruginosa, E.Coli O157:H7 and Vancomycin-resistant Enterococcus faecalis. According to a research by Hospital Attikon, Medical School of Athens, Greece, scientists came to the conclusion that Copper alloys reduced the number of viable carbapenemaseproducing bacteria significantly in 3 hours and produced a bactericidal effect in 5 hours. The pure Cu99% was more effective than cooper alloy Cu64% -Zn36%. These data suggest that the use of copper as surface material in the hospital could aid in diminishing the environmental reservoir of Methicillin Drug Resistant Gram-negatives 25. Further Activities Up until now, all researches and applications appear to have great potential regarding the effectiveness of Antimicrobial Copper Alloys against bacteria and other pathogenic organisms. 4
5 There are several theories for the mechanism by which copper kills bacteria, including: Causing leakage of potassium or glutamate through the outer membrane of bacteria Disturbing osmotic balance Binding to proteins that do not require copper Causing oxidative stress by generating hydrogen peroxide. The use of a Copper Alloy surface is a supplement to, and not a substitute for, standard infection control practices; users must continue to follow all current infection control practices, including those practices related to cleaning and disinfection of environmental surfaces. The Copper Alloy surface material has been shown to reduce microbial contamination, but it does not necessarily prevent cross contamination. Indicative objects or touch surfaces that can be replaced by objects made of Antimicrobial Copper Alloys. (Antimicrobial Copper - A Global Overview Tokuda Hospital, Sofia -1April 2011) 30 Further to the research s results, manufactures have shown great interest in producing a variety of objects that are used frequently in nosocomial areas(e.g. ICU etc.), using Antimicrobial Copper Alloys. However, the implementation outside hospital areas where microbial flora is at high levels, with increased risk of contamination worries public health planners. In Laval France, the new Center Inter-Generational Multi Accueil (CIGMA) 26, a nursery for 35 infants and a 60 bed care home for dependent elderly people copperized all handrails and doorhandles. In Tokyo, Japan the Mejiro Daycare Center for Children copperized all touch surfaces 27. In Athens Greece a big private elementary school with 2500 students changed all the handrails, doorhandles and touch surfaces of doors with cooper alloy Cu64% -Zn36%. 5
6 The first results showed % less contamination on them than on standard non copper surfaces 28. Antimicrobial Copper objects costs is a combination of raw material cost and manufacturing cost. In general the total cost is not high 31. Due to the antimicrobial efficacy, cost of object replacement and implementation, cannot be compared to the cost of objects made by other type of materials (stainless steel, plastic etc.) Microbial flora decrease results to antibiotics usage decrease, which leads to the reduction of patient s hospitalization. Cooper Alloys antimicrobial activity when compared to amnoglycocides against mutidrag resistance bacteria (Escherichia coli, Klebsiella spp, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecium) isolated from blood culture patients with signs of infection of fever appearing any time after 8 days of admission into ICU, showed that the inhibition zone of antimicrobial copper where equal to those of Aminoglycosides (2011). The above research took place at Hospital ARETAIEIO Medical School of Athens, Greece 29. Acknowledgements I thank, Prof.E. Kouskouni M.D.,Ph.D., K. Karageorgou M.D.,D.Sc, A. Vilaeti M.D., Z. Manolidou R.N.,M.Sc., M. Tseroni R.N.,M.Sc., I. Agrafa for expert advices in the study. In times where multi - resistant to antibiotics bacteria are increased, and the possibility of the end of antibiotics is near, Antimicrobial Copper Era has come to light. Corresponding author: Mailing address: Artis 17, Amarousio P.C.15125,GREECE Phone: , Fax: panosefstathiou@usa.net 6
7 BIBLIOGRAFY 1. Fleming Alexander, Biography- Wikipedia. The free encyclopedia. 2. Efstathiou P., Antimicrobial Copper a revolution in the field of prevention ESNE NATIONAL CONGRESS, CHIOS- GREECE, May Efstathiou P., Antimicrobial action of Copper, 2 nd Copper Day, H.I.C.D.- Thessaloniki -Greece, 5 Οct Robert S. Deane, M.B.B. Ch., Ernest L. Mills, M.D. and Aubert J. Hamel Antimicrobial Action of Cooper in Respiratory Therapy Apparatus, Chest, Vol. 58, No 4, Oct Kuhn P.J. Doorknobs: A source of Nosocomial infection? Diagnostic Medicine, Nov/Dec Poultsides LA., Liaropoulos LL, and Malizos KN.: The Socioeconomic Impact of Musculoskeletal Infections - Journal of Borne & Joint Surg. Am. 2010; 92: WHO, Health Care Associated Infections Fact Sheet, ECDC, Rapid Risk Assessment outbreak of Shiga toxin-producing. E.Coli (stec)in Germany 27May European Centre for Disease Prevention and Control (ECDC) Annual Epidemiological report Public Health Reports Estimating Health Care-Associated Infections and Deaths in U.S. Hospital s, 2002 Research Articles 160, March April 2007 / Volume Hirsch B.E.,Schmidt M.G., et all, Copper Surfaces Reduce Microbial Burden in Out-Patients Infections Disease Practice.poster at the ICAAC Boston, MA Sept 13, WHO, Report on the Burden of Endemic Health Care-Associated Infection Worldwide Clean Care is Safer Care, EPIC Guidelines for Preventing Health Care Associated Infections, Journal of Hospital Infection (2001) 47 (Supplement):S1doi: /jhin Noyce J.O., H.Michels, C.W. Keevil Use of Copper Cast Alloys to Control Escherichia Coli O157 Cross- Contamination during Food Processing, Applied and Environmental Microbiology, June 2006, p NoyceJ.O. H.Michels and C.W.Keevil1. Inactivation of Influenza A Virus on Copper versus Stainless Steel Surfaces. Applied and Environmental Microbiology, Apr.2007, p , Vol.73, No Weavera L., H.T. Michelsb, C.W. Keevila. Survival of Clostridium difficile on copper and steel: Futuristic options for hospital hygiene. J Hosp Infect (2008), doi: /j.jhin Wheeldon L.J., T. Worthington1, P.A. Lambert, A.C. Hilton,.J. Lowden and T.S.J. Elliot.. Antimicrobial efficacy of copper surfaces against spores and vegetative cells of Clostridium difficile: the germination theory. Journal of Antimicrobial Chemotherapy (2008) 62, , doi: /jac/dkn219, 10 June Sasahara T, Niiyama N and Ueno M. Use of Copper and its Alloys to Reduce Bacterial Contamination in Hospitals (Invited lecture), Journal of the JRICu Vol.46 No.1 (2007). 19. Casey Al et al. Role of copper in reducing hospital environment 7
8 contamination, J Hosp. Infect (2009), doi: /j.jhin Prado V, Duran C, Crestto M et al. Effectiveness of copper contact surfaces in reducing the microbial burden (MB) in the intensive care unit (ICU) of Hospital del Cobre, Calama, Chile. Poster , 14th.International Conference on Infectious Diseases, Miami, March 11, Reducing the risk of HCAI AskLepios Hospital, Homburg, and Germany. CDA196. p6, Reducing the risk of HCAI Helsinki University, Finland. CDA196. P6, Michels HT and Anderson DG. Antimicrobial regulatory efficacy testing of solid copper alloy surfaces in the USA,. pp , Metal Ions in Biology and Medicine: Vol Salgado CD, Morgan A, Sepkowitz KA et al. A pilot study to determine the effectiveness of copper in reducing the microbial burden (MB) of objects in rooms of intensive care unit (ICU) patients. Poster 183, 5th Decennial International Conference on Healthcare- Associated Infections, Atlanta, March 19, Armaganidis A., et al. Evaluation of copper-containing items for reducing environmental contamination with multidrug-resistant bacteria in a University Hospital ICU-2nd Department of Critical Care Medicine, Athens University School of Medicine, University General Hospital ATTIKO. 26. Pioneering Eco Care Home Specifies Antimicrobial Copper Laval, France- CDA, PR799-9Feb Antimicrobial Copper to Protect Children against Infections-Tokyo, Japan-CDA-PR797-Jan Efstathiou P.,et al. Elementary schools in Athens -Application of Antimicrobial Copper. XVI Congreso Nacional y V Internacional de la Sociedad Española de Medicina Preventiva Salud Publica e Higiene, Maspalomas, Gran Canaria 25/27 May Kouskouni E., I. Tsouma, I. Patikas, K. Karageorgou, Z. Manolidou, M. Tseroni, M. Agrafa, P.Efstathiou (ATHENS, Gr) Antimicrobial Activity of Copper Alloys compared to Aminoglycosides against multidrug resistant bacteria ECCMID-ICC Abst. Nr Vessey Angela, Antimicrobial Copper - A Global Overview, European Antimicrobial Copper Programme Tokuda Hospital, Sofia,Bulgaria - 1April Peter Sharpe -Business Case for AM Copper Alloys (presentation) February 11,
New and Innovative Applications for Metals COPPER. Tony Lea International Copper Association
New and Innovative Applications for Metals COPPER Tony Lea International Copper Association SUPERBUGS 2 HOSPITAL ACQUIRED INFECTIONS Infections acquired during hospital stays kill more people than breast
More informationAntimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention
Antimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention Wilton Moran Project Engineer Copper Development Association The Science Behind the Technology Digital Summit Infection
More informationProblem: Hospital Acquired Infections
Antimicrobial Copper: new market opportunities International Copper Association Codelco Problem: Hospital Acquired Infections 2 Hospital acquired infections (HAIs): Worldwide 7,000,000 infections per year
More informationAntimicrobial Copper Touch Surfaces for Infection Prevention and Control
Antimicrobial Copper Touch Surfaces for Infection Prevention and Control Content 01.00 Introduction 02.00 Laboratory Science 03.00 Clinical Evidence 04.00 Recognition in Guidelines and Rating Systems 05.00
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationAHFA 2016 Regulatory Summit. Antimicrobial Material Preservatives & Sustainability Considerations
Material AHFA 2016 Regulatory Summit Scientific and Regulatory Excellence Antimicrobial Material Preservatives & Sustainability Considerations Erin Tesch Technology Sciences Group Inc. (TSG) 1150 18 th
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationMICRO-ORGANISMS by COMPANY PROFILE
MICRO-ORGANISMS by COMPANY PROFILE 2017 1 SAPROPHYTES AND PATHOGENES SAPROPHYTES Not dangerous PATHOGENES Inducing diseases Have to be eradicated WHERE ARE THERE? EVERYWHERE COMPANY PROFILE 2017 3 MICROORGANISMS
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationSYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data
508 SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data Physical Properties Active Ingredient: Ethyl Alcohol 62% (70% v/v) Appearance: Clear, Colorless Solution Fragrance: Floral Form:
More informationThe Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University
The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3 Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University Tae-yoon Choi ABSTRACT BACKGROUND: The use of disinfectants
More informationOverview of Infection Control and Prevention
Overview of Infection Control and Prevention Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control Terry Green and Salah Gammouh
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationSYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data
408 SYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data Physical Properties Active Ingredient: Chloroxylenol (PCMX) 0.3% Appearance: Clear, Amber Solution Fragrance: Floral Form: Liquid
More informationMulti-Drug Resistant Organisms (MDRO)
Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause
More informationSurveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe
Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe Carl Suetens, ECDC Presented by Håkan Hanberger ecdc.europa.eu Message/Questions from C Suetens to Workshop 7, MIE2009
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More informationAntimicrobial Activity of Copper Alloys Against Invasive Multidrug-Resistant Nosocomial Pathogens
Curr Microbiol (215) 71:291 295 DOI 1.17/s284-15-84-8 Antimicrobial Activity of Copper Alloys Against Invasive Multidrug-Resistant Nosocomial Pathogens Ozgen Koseoglu Eser 1 Alper Ergin 2 Gulsen Hascelik
More informationLiofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms
Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective
More informationTest Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants
Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified
More informationWhat is the problem? Latest data on antibiotic resistance
European Antibiotic Awareness Day 2009 What is the problem? Latest data on antibiotic resistance Zsuzsanna Jakab, ECDC Director Launch Seminar for EAAD Stockholm, 18 November 2009 Fluoroquinolone-resistant
More informationRisk of organism acquisition from prior room occupants: A systematic review and meta analysis
Risk of organism acquisition from prior room occupants: A systematic review and meta analysis A/Professor Brett Mitchell 1-2 Dr Stephanie Dancer 3 Dr Malcolm Anderson 1 Emily Dehn 1 1 Avondale College;
More informationEpidemiology and Economics of Antibiotic Resistance
Epidemiology and Economics of Antibiotic Resistance Eili Y. Klein February 17, 2016 Health Watch USA Meeting I. The burden of antibiotic resistance is a growing global threat, but hard numbers are lacking
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationObjectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017
Basic Microbiology Vaneet Arora, MD MPH D(ABMM) FCCM Associate Director of Clinical Microbiology, UK HealthCare Assistant Professor, Department of Pathology and Laboratory Medicine University of Kentucky
More informationHand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY
Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY MDROs and Hand Hygiene Guidelines HH Apr14 The Science of Hand Hygiene in Healthcare Settings
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationCAVICIDE1. Technical Bulletin
CAVICIDE1 Technical Bulletin CaviCide1 is a multi-purpose disinfectant intended for use in cleaning, decontaminating and disinfecting hard non-porous, inanimate surfaces and non-critical instruments in
More informationThe challenge of growing resistance
EXECUTIVE SUMMARY Around 2.4 million people could die in Europe, North America and Australia between 2015-2050 due to superbug infections unless more is done to stem antibiotic resistance. However, three
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationReport on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationWhat bugs are keeping YOU up at night?
What bugs are keeping YOU up at night? Barbara DeBaun, RN, MSN, CIC 26 th Annual Medical Surgical Nursing Conference South San Francisco, CA April 15, 2016 Objectives Describe the top three infectious
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationPost-operative surgical wound infection
Med. J. Malaysia Vol. 45 No. 4 December 1990 Post-operative surgical wound infection Yasmin Abu Hanifah, MBBS, MSc. (London) Lecturer Department of Medical Microbiology, Faculty of Medicine, University
More informationAMR epidemiological situation: ECDC update
One Health Network on Antimicrobial Resistance (AMR) AMR epidemiological situation: ECDC update Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI)
More informationTackling the need for new antibacterial drugs
Tackling the need for new antibacterial drugs Wendy Lawson Lead Pharmacist, Infectious Diseases Imperial College Healthcare NHS Trust, London & Antibiotic Action Champion Timeline of Antibiotic Discovery
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationINFECTION PREVENTION SILVER ANTI-MICROBIAL TEXTILES
INFECTION PREVENTION SILVER ANTI-MICROBIAL TEXTILES Agenda SILVERGUARD background Infection management challenges and the SILVER antimicrobial technology solution Case studies and clinical data SILVERGUARD
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationZoonoses in the EU and global context
Zoonoses in the EU and global context Conference "One world One health. Zoonoses and good practice" 16 October 2018 Vilnius, Lithuania Ángela Bolufer de Gea Unit G4 - Food hygiene Directorate G - Crisis
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationAntimicrobial stewardship in companion animals: Welcome to a whole new era
Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationTaking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms
Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National
More informationMultidrug Resistant Organisms (MDROs) and Clostridium difficile (C. diff)
PATIENT & CAREGIVER EDUCATION Multidrug Resistant Organisms (MDROs) and Clostridium difficile (C. diff) This information explains multidrug resistant organisms (MDROs) and Clostridium difficile (C. diff),
More informationTwo (II) Upon signature
Page 1/5 SCREENING FOR ANTIBIOTIC RESISTANT ORGANISMS (AROS) IN ACUTE CARE AND LONG TERM CARE Infection Prevention and Control IPC 050 Issuing Authority (sign & date) Office of Administrative Responsibility
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationAntimicrobial Resistance. The Case for Diagnostics to Better Direct Therapy
Antimicrobial Resistance The Case for Diagnostics to Better Direct Therapy Objectives Explain the medical significance of antibiotic resistance Assess the medical impact of disease, such as pneumonia and
More informationRole of the nurse in diagnosing infection: The right sample, every time
BROUGHT TO YOU BY Role of the nurse in diagnosing infection: The right sample, every time The module has been written by Shanika Anne-Marie Crusz and Amelia Joseph Authors affiliation: Department of Clinical
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationPreventing Clostridium difficile Infection (CDI)
1 Preventing Clostridium difficile Infection (CDI) All Hands on Deck to Reduce CDI Skill Nursing Facility Conference July 28, 2017 Idamae Kennedy, MPH,BSN,RN,CIC Liaison Infection Preventionist Healthcare
More informationNo-leaching. No-resistance. No-toxicity. >99.999% Introducing BIOGUARD. Best-in-class dressings for your infection control program
Introducing BIOGUARD No-leaching. >99.999% No-resistance. No-toxicity. Just cost-efficient, broad-spectrum, rapid effectiveness you can rely on. Best-in-class dressings for your infection control program
More informationThe Hospital Environment as a Source of Resistant Gram Negatives
Avondale College ResearchOnline@Avondale Nursing and Health Conference Papers Faculty of Nursing and Health 2013 The Hospital Environment as a Source of Resistant Gram Negatives Brett G. Mitchell Avondale
More informationAn Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?
An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? Dr. Andrew Morris Antimicrobial Stewardship ProgramMt. Sinai Hospital University Health Network amorris@mtsinai.on.ca andrew.morris@uhn.ca
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationECDC activities on antimicrobial resistance & healthcare-associated infections (ARHAI Programme) Ülla-Karin Nurm, ECDC Tallinn, 13 May 2013
ECDC activities on antimicrobial resistance & healthcare-associated infections (ARHAI Programme) Ülla-Karin Nurm, ECDC Tallinn, 13 May 2013 What is the European Union? 27 Member States 24 official languages
More informationRise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University
Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Willard Wigan Microbiologists grow bacteria on plates Each colony is formed from a single cell Colonies
More informationThe relevance of Gram-negative pathogens for public health situation in India
The relevance of Gram-negative pathogens for public health situation in India Dr. Sanjay Bhattacharya MD, DNB, DipRCPath, FRCPath, CCT (UK) Consultant Microbiologist Tata Medical Center www.tmckolkata.com
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationStratégie et action européennes
Résistance aux antibiotiques : une impasse thérapeutique? Implications nationales et internationales Stratégie et action européennes Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial
More informationMethicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus By Karla Givens Means of Transmission and Usual Reservoirs Staphylococcus aureus is part of normal flora and can be found on the skin and in the noses of one
More informationSurveillance of Multi-Drug Resistant Organisms
Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine
More informationInterrupting The ECMO Circuit
Extracorporeal Membrane Oxygenation Program Interrupting The ECMO Circuit Mark Lucas, MPS, CCP, ECMO Coordinator Leo Carr, MS, CCP, Lead Perfusionist Objectives Discuss the need for interrupting the ECMO
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives John Jernigan, MD, MS Alex Kallen, MD, MPH Division of Healthcare Quality Promotion Centers for Disease
More informationANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES
ANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES 1 Crisis: Antibiotic Resistance Success Strategy 2 OBJECTIVES Discuss
More informationBIOL 2900 D 4.00 Microbiology in Health/Disease
SYLLABUS BIOL 2900 - D Spring, 2017 Course: Microbiology in Health and Disease Instructor: Prafull C. Shah Office Hours: Before or after classes, or by appointment by Email to pcshah@valdosta.edu. Semester
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More informationA solution for current veterinary challenges
A solution for current veterinary challenges 2 www.jakmarketing.co.uk Introduction The current disease challenge in veterinary practices is increasingly coming from pathogens that are resistant to both
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationDr Nata Menabde Executive Director World Health Organization Office at the United Nations Global action plan on antimicrobial resistance
Global action plan on antimicrobial resistance Dr Nata Menabde Executive Director World Health Organization Office at the United Nations Proportion of MDR among previously treated TB cases, 1994-2010 0-
More informationCourse: Microbiology in Health and Disease
SYLLABUS BIOL 2900 SECTION D SPRING 2012 Course: Microbiology in Health and Disease BIPIN PATEL Office Hours: Before or after Class or by appointment Semester Begins JANUARY 09 TO MAY 04 2012 2900 D 4.00
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationCourse: Microbiology in Health and Disease Office Hours: Before or after Class or by appointment
SYLLABUS BIOL 2900 SECTIONS C AND D Spring, 2011 Course: Microbiology in Health and Disease Office Hours: Before or after Class or by appointment Semester Begins on January 10, 2011 and ends on May 2,
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationNosocomial Antibiotic Resistant Organisms
Nosocomial Antibiotic Resistant Organisms Course Medical Microbiology Unit II Laboratory Safety and Infection Control Essential Question Does improved hand hygiene really reduce the spread of bacteria
More informationImplementation of a National Action Plan and International standards especially with regard to Responsible and prudent use of antimicrobials
Implementation of a National Action Plan and International standards especially with regard to Responsible and prudent use of antimicrobials Dr. Sasi Jaroenpoj, D.V.M Head of Veterinary Products and AMR
More informationAntimicrobial resistance and antimicrobial consumption in Europe
Antimicrobial resistance and antimicrobial consumption in Europe Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Programme Vilnius, 28 November
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationANTIBIOTIC RESISTANCE. Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh
ANTIBIOTIC RESISTANCE Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More information28/08/2017. Infection Prevention and Control. Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR
Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR 2017 Safe Patient Care 2017: The Ongoing Challenge of MDROs and AMR Management of the Patient Environment in relation to Multidrug
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More information